Cancer News: Skin

Adjuvant therapy with ipilimumab may improve survival in melanoma

Overall survival in patients with stage 3 melanoma can be significantly increased with ipilimumab as adjuvant therapy.

Ipilimumab with local treatments improved survival in melanoma

Adding local peripheral treatments to systemic ipilimumab increased survival in melanoma patients, a retrospective analysis shows.

Skin cancer combo shows evidence against lung cancer

Novartis's drug combination of Tafinlar and Mekinist increased progression-free survival in lung cancer patients almost up to 10 months, said the company.

PD-1 inhibitors hold promise for melanoma patients

In two studies, the PD-1 inhibitors pembrolizumab and nivolumab produced long-duration disease control and long-term survival for some melanoma patients.

Immunotherapy and radiation: synergy against melanoma

Treating advanced melanoma patients with radiation combined with immunotherapy induces better results against melanoma, a research shows.

Pembrolizumab increases long-term survival in advanced myeloma

Advanced melanoma patients lived longer after being treated with pembrolizumab regardless of whether they received previous treatments, a study shows.

Opdivo increased survival in pre-treated melanoma

Treating patients with previously treated melanoma with immunotherapeutic agent nivolumab Opdivo resulted in an increase in their overall survival, data showed.

Adding vemurafenib to cobimetinib: beneficial against melanoma

Cobimetinib in combination with vemurafenib found to be even more beneficial than cobimetinib alone for melanoma patients, a new study reports.

Men with advanced melanoma benefited by dabrafenib/trametinib combo

A new analysis reveals that men with advanced melanoma benefited from a combination treatment of dabrafenib and trametinib.

Tracking tumor DNA in the blood reveals skin cancer relapse

Scientists were able to see whether a patient with advanced melanoma skin cancer is relapsing by tracking levels of circulating tumor DNA in the blood.

Linking the number of moles with tumor thickness in melanoma

A new study of the association between moles and tumor thickness found that having less moles is associated with reduced risk for thick melanoma.

Unraveling melanoma diagnosis and treatments

Melanoma rates have doubled although today we have more tools than even to diagnose melanoma, including genetic and molecular testing.

Nivolumab gets NICE recommendation for advanced skin cancer

NICE recommends nivolumab as a treatment for advanced, unresectable or metastatic melanoma.

Combination treatment approved for melanoma

US regulators approved the combination of nivolumab plus ipilimumab for the treatment of unresectable or metastatic melanoma.

Advanced melanoma: immunotherapy approved as first line treatment

The novel immunotherapy pembrolizumab was approved by the U.S. FDA as first-line treatment for metastatic melanoma.

EU gets closer to the treatment of Merkel cell carcinoma

European regulators have taken a step closer to the treatment of Merkel cell carcinoma, adopting a positive opinion for Orphan Drug designation for avelumab.

FDA approves drug combination for skin cancer

U.S. regulators approved Novartis’ drug combination of Tafinlar and Mekinist for the treatment of metastatic melanoma.

Extended survival with combination treatment in skin cancer

Combing cobimetinib and vemurafenib extended the survival rate of previously untreated patients with advanced skin cancer, a new study reports.

Pancreatic cancer immunotherapy shows promise in melanoma

According to latest five year survival clinical results, patients with metastatic melanoma were benefited by IMM-101, a pancreatic cancer immunotherapy drug.

One step closer to the treatment of Merkel cell carcinoma

U.S. regulators granted breakthrough therapy designation to avelumab for the treatment of patients with metastatic Merkel cell carcinoma.

New treatment approved for advanced melanoma

The U.S FDA approved Cotellic for the treatment of patients with untreated BRAF V600 mutation-positive advanced melanoma.

FDA expands the use of melanoma drug Yervoy

Patients with stage III melanoma with a high risk of recurrence after surgery can now be treated with Yervoy as the FDA has expanded the use of this melanoma drug.

Viral immunotherapy gets EU approval for melanoma

A viral immunotherapy got approved by EU regulators for the treatment of melanoma patients.

Combining immunotherapy with radiation therapy for melanoma patients

A subset of patients with metastatic melanoma benefited from a combined treatment of immunotherapy and palliative radiation therapy, a new research reveals.

Surgical resection induces better responses in melanoma patients

Surgical removal of metastatic melanoma helped patients live more than twice as long as those who receive only medical therapy, according to the results of a new study.

Combination immunotherapy for advanced melanoma approved by the FDA

U.S. regulators approved the combination of the immunotherapies nivolumab and ipilimumab for the treatment of patients with melanoma without a BRAF mutation.

New combination therapy boosts survival in melanoma patients

Patients of advanced BRAF-mutant melanoma survived longer when treated with a combination of the targeted therapies dabrafenib and trametinib.

Skin cancer combination therapy one step closer to EU approval

Roche’s combination therapy for skin cancer received a positive opinion from the European Commission, bringing closer the approval of the drug for European patients.

Immunotherapy may not be a treatment option for some melanoma patients

Immunotherapy drug ipilimumab benefited only melanoma patients with a specific type of tumor-produced antigens, a new study reveals.

Two targeted therapies get European recommendation for melanoma

The combination of dabrafenib and trametinib got recommended by European regulators to treat adult melanoma patients with a BRAF V600 mutation.

Login to your account

Did you forget your password?